Psoriasis PBMC

Psoriasis PBMC for Immune-Mediated Inflammatory Skin Disease Research

Psoriasis PBMC products are sourced from IRB-consented donors clinically diagnosed with psoriasis and processed within 24 hours of collection under stringent conditions. Psoriasis is an immune-mediated inflammatory disease of the skin driven by the IL-23/Th17 axis – it is not autoantibody-mediated – and cryopreserved peripheral blood mononuclear cells provide the T-cell and myeloid material required to study that pathway ex vivo.

Psoriasis Immunology and Why PBMCs

• Psoriasis is sustained by a self-amplifying loop between keratinocytes and immune cells rather than by autoantibodies. Dendritic cell-derived IL-23 drives Th17 differentiation and survival, and the resulting IL-17A, IL-17F, and IL-22 output activates keratinocytes, which in turn recruit more immune cells.
• Plasmacytoid dendritic cells and type I interferon signalling are implicated in lesion initiation, while TNF acts throughout the amplification loop. The clinical efficacy of IL-17, IL-23, and TNF inhibitors validates this hierarchy directly.
• HLA-C*06:02 is the strongest genetic association, particularly with early-onset disease, and additional risk loci implicate IL23R, IL12B, and NF-kB regulatory genes.
• Circulating Th17 and Tc17 cells, CCR6+ skin-homing populations, and IL-17-producing innate-like lymphocytes are measurable in peripheral blood and track with disease activity, so blood-derived cells give a tractable window onto lesional biology.
• PBMCs support in vitro stimulation to interrogate cytokine production capacity and drug effects on the IL-23/IL-17 axis – functional readouts that cannot be obtained from plasma or serum.
• Psoriasis and psoriatic arthritis share this seronegative, IL-23/IL-17-driven mechanism; up to a third of psoriasis patients develop joint involvement, making donor arthritis status an important stratification variable.

Donor Stratification Available

• Disease severity: PASI or affected body surface area where documented
• Clinical subtype: plaque, guttate, inverse, pustular, or erythrodermic psoriasis
• Presence or absence of concomitant psoriatic arthritis
• Treatment exposure: biologic-naive, anti-IL-17, anti-IL-23/IL-12-23, anti-TNF, or JAK/TYK2 inhibitor treated; topical and phototherapy background
• Age at onset: early-onset versus late-onset disease, and disease duration
• Relevant comorbidities including metabolic syndrome, and HLA-C*06:02 status where typing is available
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMC
• Clinically confirmed psoriasis donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified psoriasis diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Disease severity, subtype, and treatment history where documented
• Additional psoriasis-specific data available upon request

Applications

• Immunophenotyping of Th17, Tc17, Treg, and CCR6+ skin-homing subsets by flow or spectral cytometry
• In vitro stimulation assays measuring IL-17A, IL-17F, IL-22, and IFN-gamma production capacity
• Ex vivo drug screening and mechanism-of-action work for IL-17, IL-23, TNF, and TYK2/JAK-targeted agents
• Dendritic cell and monocyte functional assays, including type I interferon response profiling
• Single-cell RNA sequencing, CITE-seq, and TCR repertoire analysis
• Transcriptomic and proteomic profiling of sorted immune subsets
• Biomarker discovery and validation for treatment response and relapse prediction
• Assay development and qualification for clinical research immune monitoring panels

Other Psoriasis Specimen Types

• Psoriasis Plasma
• Psoriasis Serum
• Psoriasis Whole Blood
• Psoriasis Leukopak
• Psoriasis Skin Punch Biopsy
• Psoriasis Bulk Plasma

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Psoriasis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. Browse all human PBMCs or request a custom disease-state collection.